InsiderTrades

Form 4 for NBIX NEUROCRINE BIOSCIENCES INC

Accepted 2026-02-03 00:00:00 ET · period of report 2026-01-31 · accession 0001776977-26-000005 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X Filed Traded Ticker Insider Title Type Price Qty Owned ΔOwn Value
D 2026-02-03 2026-01-31 NBIX Cooke Julie CHRO M - OptEx $0.00 +1,741 28.6K +6% $0
D 2026-02-03 2026-01-31 NBIX Cooke Julie CHRO F - Tax $136.06 -997 27.6K -3% -$135.7K
D 2026-02-03 2026-01-31 NBIX Cooke Julie CHRO M - OptEx $0.00 -1,741 0 -100% $0

Purchase Sale Sale after option exercise All abbreviations

Every reported transaction

#TableSecurityDateCodeA/DSharesPriceOwned afterOwnExercise / expiryUnderlyingFootnotes
1 Common Common Stock 2026-01-31 M A 1,741 $0.00 28,599 D — —
2 Common Common Stock 2026-01-31 F D 997 $136.06 27,602 D — — (F1) Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs"). No shares were sold. (F2) 25,738 of the reported shares are held by the Cooke Family Trust of 2004 U/A 12/28/2004, of which the Reporting Person has voting and investment power.
3 Derivative Restricted Stock Unit 2026-01-31 M D 1,741 $0.00 0 D — · — to — 1,741 Common Stock (F3) Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. (F4) This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 1,740 shares on January 31, 2023, vested as to 1,740 shares on January 31, 2024, vested as to 1,740 shares on January 31, 2025, and vested as to 1,741 shares on January 31, 2026, subject to the terms and conditions of the award.